# Role of IL-17 Cytokine Networks in TB Relapse Due to HIV

> **NIH NIH R01** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $574,424

## Abstract

Abstract
Tuberculosis (TB) claims the lives of 4,000 individuals every day as the leading cause of death due to infectious
disease. In those with human immunodeficiency virus (HIV) infection, however, the risk for TB treatment failure
or post-therapy relapse is greatly increased. TB relapse is strongly associated with development of drug
resistance and occurs through poorly understood effects of HIV on host immunity. Understanding the HIV factors
driving TB relapse, then, represents an important gap in knowledge needed for development of interventions
that support immune containment and complement drug therapy. We describe the first animal model of HIV-
mediated TB relapse following drug treatment, using the humanized mouse. Our preliminary data suggests that
defects in activation of IL-17 pathways due to HIV infection are a potential mechanism for loss of immunity to the
causative agent of TB, Mycobacterium tuberculosis (Mtb). Based on these findings, we hypothesize that Th17
T cells play an important role in containment of paucibacillary TB following drug therapy that is compromised by
HIV infection. Our collaborative group previously conducted investigations of T cell immune defects in HIV+ and
HIV- human subjects in Nairobi, Kenya, who had recently completed the intensive phase of TB chemotherapy.
We propose to expand our investigations to now demonstrate how HIV status effects Th17 cell memory function
following TB chemotherapy in virally suppressed and non-suppressed people. We propose to further use our
humanized mouse model of HIV-mediated TB relapse to identify the mechanistic role of Th17 cells and IL-17 in
TB containment, and demonstrate how activation of Th17 cells during the immune response to Mtb promotes
virus propagation in the lung. We propose the following specific aims: 1) Aim 1, Poor recovery or dysfunction of
the Th17 compartment predicts post-chemotherapy TB relapse in human subjects with HIV; and 2) Aim 2, HIV
co-infection perturbs protective function of Th17/IL-17 as a mechanism for driving Mtb relapse following TB drug
therapy in co-infected humanized mice. We expect these results to inform efforts to target the IL-17 cytokine
family in development of preventive measures to reduce TB recurrence in those at risk due to HIV co-infection.

## Key facts

- **NIH application ID:** 10168447
- **Project number:** 5R01AI147948-03
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** Evans I Amukoye
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $574,424
- **Award type:** 5
- **Project period:** 2019-06-21 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10168447

## Citation

> US National Institutes of Health, RePORTER application 10168447, Role of IL-17 Cytokine Networks in TB Relapse Due to HIV (5R01AI147948-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10168447. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*